Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,22732766,time to maximum plasma concentration (t(max)),The plasma vardenafil concentration increased rapidly and exhibited a median time to maximum plasma concentration (t(max)) of 1 h and a mean elimination half-life (t(1/2)) of 3.4 h.,High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732766/),h,1,1895,DB00559,Bosentan
,22732766,elimination half-life (t(1/2)),The plasma vardenafil concentration increased rapidly and exhibited a median time to maximum plasma concentration (t(max)) of 1 h and a mean elimination half-life (t(1/2)) of 3.4 h.,High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732766/),h,3.4,1896,DB00559,Bosentan
,22732766,peak plasma concentration (C(max)),"The geometric mean and standard deviation of (1) the peak plasma concentration (C(max)) was 21.4 ± 1.7 μg/L, (2) the normalized C(max) (C(max, norm)) 79.1 ± 1.6 g/L, (3) the area under the time-concentration curve (AUC) 71.5 ± 1.6 μg · h/L and (4) the normalized AUC (AUC(norm)) 261.6 ± 1.7 g · h/L.",High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732766/),[μg] / [l],21.4,1897,DB00559,Bosentan
,22732766,normalized,"The geometric mean and standard deviation of (1) the peak plasma concentration (C(max)) was 21.4 ± 1.7 μg/L, (2) the normalized C(max) (C(max, norm)) 79.1 ± 1.6 g/L, (3) the area under the time-concentration curve (AUC) 71.5 ± 1.6 μg · h/L and (4) the normalized AUC (AUC(norm)) 261.6 ± 1.7 g · h/L.",High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732766/),[g] / [l],79.1,1898,DB00559,Bosentan
,22732766,C(max) (C(max,"The geometric mean and standard deviation of (1) the peak plasma concentration (C(max)) was 21.4 ± 1.7 μg/L, (2) the normalized C(max) (C(max, norm)) 79.1 ± 1.6 g/L, (3) the area under the time-concentration curve (AUC) 71.5 ± 1.6 μg · h/L and (4) the normalized AUC (AUC(norm)) 261.6 ± 1.7 g · h/L.",High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732766/),[g] / [l],79.1,1899,DB00559,Bosentan
,22732766,area under the time-concentration curve (AUC),"The geometric mean and standard deviation of (1) the peak plasma concentration (C(max)) was 21.4 ± 1.7 μg/L, (2) the normalized C(max) (C(max, norm)) 79.1 ± 1.6 g/L, (3) the area under the time-concentration curve (AUC) 71.5 ± 1.6 μg · h/L and (4) the normalized AUC (AUC(norm)) 261.6 ± 1.7 g · h/L.",High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732766/),[h·μg] / [l],71.5,1900,DB00559,Bosentan
,22732766,normalized,"The geometric mean and standard deviation of (1) the peak plasma concentration (C(max)) was 21.4 ± 1.7 μg/L, (2) the normalized C(max) (C(max, norm)) 79.1 ± 1.6 g/L, (3) the area under the time-concentration curve (AUC) 71.5 ± 1.6 μg · h/L and (4) the normalized AUC (AUC(norm)) 261.6 ± 1.7 g · h/L.",High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732766/),[g·h] / [l],261.6,1901,DB00559,Bosentan
,22732766,AUC (AUC(norm)),"The geometric mean and standard deviation of (1) the peak plasma concentration (C(max)) was 21.4 ± 1.7 μg/L, (2) the normalized C(max) (C(max, norm)) 79.1 ± 1.6 g/L, (3) the area under the time-concentration curve (AUC) 71.5 ± 1.6 μg · h/L and (4) the normalized AUC (AUC(norm)) 261.6 ± 1.7 g · h/L.",High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732766/),[g·h] / [l],261.6,1902,DB00559,Bosentan
,12047483,tmax,"Bosentan was absorbed and eliminated with a tmax of 4.5 h (range 3.5-6.0 h) and a t(1/2) of 5.4 h (95% CI; 4.5, 6.6).",Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12047483/),h,4.5,12545,DB00559,Bosentan
,12047483,t(1/2),"Bosentan was absorbed and eliminated with a tmax of 4.5 h (range 3.5-6.0 h) and a t(1/2) of 5.4 h (95% CI; 4.5, 6.6).",Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12047483/),h,5.4,12546,DB00559,Bosentan
,8823230,Systemic plasma clearance,"Systemic plasma clearance and volume of distribution decreased with increasing dose to limiting values of around 6 L/hr and 0.2 L/kg, respectively.",Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823230/),[l] / [h],6,21758,DB00559,Bosentan
,8823230,volume of distribution,"Systemic plasma clearance and volume of distribution decreased with increasing dose to limiting values of around 6 L/hr and 0.2 L/kg, respectively.",Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823230/),[l] / [kg],0.2,21759,DB00559,Bosentan
,8823230,absolute bioavailability,The absolute bioavailability was 50% and appeared to decrease with doses above 600 mg.,Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823230/),%,50,21760,DB00559,Bosentan
,32871206,MMAD,"These microparticles had not only the significantly highest aerosol performance (MMAD of 1.91 μm and FPF of 51.68%) in the formulations, but also significantly increased dissolution rate, compared with the raw bosentan hydrate.",Inhaled bosentan microparticles for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32871206/),,1,38921,DB00559,Bosentan
,32871206,survival rate,"The survival rate of the group administrated SDBM1:1 intratracheally was 0.92 at the end of study (Positive control and orally administrated groups were 0.58 and 0.38, respectively).",Inhaled bosentan microparticles for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32871206/),,0.92,38922,DB00559,Bosentan
,32871206,survival rate,"The survival rate of the group administrated SDBM1:1 intratracheally was 0.92 at the end of study (Positive control and orally administrated groups were 0.58 and 0.38, respectively).",Inhaled bosentan microparticles for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32871206/),,0.58,38923,DB00559,Bosentan
,32871206,survival rate,"The survival rate of the group administrated SDBM1:1 intratracheally was 0.92 at the end of study (Positive control and orally administrated groups were 0.58 and 0.38, respectively).",Inhaled bosentan microparticles for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32871206/),,0.38,38924,DB00559,Bosentan
,28655665,diameters,TEM analysis indicated that the diameters of the prepared bosentan nanocomposite after dispersion in distilled water were 13.69-96.78nm.,"Effect of amphiphilic graft co-polymer-carrier on physical stability of bosentan nanocomposite: Assessment of solubility, dissolution and bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28655665/),nm,13.69-96.78,49285,DB00559,Bosentan
,15568889,absolute bioavailability,The absolute bioavailability is about 50%.,"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),%,50,73755,DB00559,Bosentan
,15568889,volume of distribution,"Bosentan is approximately 98% bound to albumin and, during multiple-dose administration, has a volume of distribution of 30 L and a clearance of 17 L/h.","Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),l,30,73756,DB00559,Bosentan
,15568889,clearance,"Bosentan is approximately 98% bound to albumin and, during multiple-dose administration, has a volume of distribution of 30 L and a clearance of 17 L/h.","Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),[l] / [h],17,73757,DB00559,Bosentan
,15568889,terminal half-life,The terminal half-life after oral administration is 5.4 hours and is unchanged at steady state.,"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),h,5.4,73758,DB00559,Bosentan
,26756977,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve of sildenafil was significantly higher in S+A treatment than in S+B treatment (165.8 ng•h/mL vs. 396.8 ng•h/mL, P = 0.018) and the oral clearance of sildenafil was significantly lower after S+A treatment than after S+B treatment (120.6 L/h/kg vs. 50.4 L/h/kg, P = 0.018).",Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26756977/),[h·ng] / [ml],165.8,74000,DB00559,Bosentan
,26756977,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve of sildenafil was significantly higher in S+A treatment than in S+B treatment (165.8 ng•h/mL vs. 396.8 ng•h/mL, P = 0.018) and the oral clearance of sildenafil was significantly lower after S+A treatment than after S+B treatment (120.6 L/h/kg vs. 50.4 L/h/kg, P = 0.018).",Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26756977/),[h·ng] / [ml],396.8,74001,DB00559,Bosentan
,26756977,oral clearance,"The area under the plasma concentration-time curve of sildenafil was significantly higher in S+A treatment than in S+B treatment (165.8 ng•h/mL vs. 396.8 ng•h/mL, P = 0.018) and the oral clearance of sildenafil was significantly lower after S+A treatment than after S+B treatment (120.6 L/h/kg vs. 50.4 L/h/kg, P = 0.018).",Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26756977/),[l] / [h·kg],120.6,74002,DB00559,Bosentan
,26756977,oral clearance,"The area under the plasma concentration-time curve of sildenafil was significantly higher in S+A treatment than in S+B treatment (165.8 ng•h/mL vs. 396.8 ng•h/mL, P = 0.018) and the oral clearance of sildenafil was significantly lower after S+A treatment than after S+B treatment (120.6 L/h/kg vs. 50.4 L/h/kg, P = 0.018).",Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26756977/),[l] / [h·kg],50.4,74003,DB00559,Bosentan
,26583764,conversion factors,"Due to poor distribution into erythrocytes, drug concentrations in DBS were always lower than in plasma, resulting in conversion factors of 1.58 for ambrisentan and sildenafil and 1.52 for bosentan and tadalafil.","Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26583764/),,1.58,77354,DB00559,Bosentan
,26583764,conversion factors,"Due to poor distribution into erythrocytes, drug concentrations in DBS were always lower than in plasma, resulting in conversion factors of 1.58 for ambrisentan and sildenafil and 1.52 for bosentan and tadalafil.","Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26583764/),,1.52,77355,DB00559,Bosentan
,28213957,AUC0-24C,"The geometric mean [95% confidence interval (CI)] for AUC0-24C was 8535 h.ng ml-1 (6936, 10 504) and 7275 h.ng ml-1 (5468, 9679) for 2 mg kg-1 b.i.d. and t.i.d., respectively [geometric mean ratio (95% CI) 0.85 (0.61, 1.20)].",A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28213957/),[h·ng] / [ml],8535,77689,DB00559,Bosentan
,28213957,AUC0-24C,"The geometric mean [95% confidence interval (CI)] for AUC0-24C was 8535 h.ng ml-1 (6936, 10 504) and 7275 h.ng ml-1 (5468, 9679) for 2 mg kg-1 b.i.d. and t.i.d., respectively [geometric mean ratio (95% CI) 0.85 (0.61, 1.20)].",A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28213957/),[h·ng] / [ml],7275,77690,DB00559,Bosentan
,28213957,CmaxC,"The geometric mean (95% CI) for CmaxC was 743 ng ml-1 (573, 963) and 528 ng ml-1 (386, 722) for 2 mg kg-1 b.i.d. and t.i.d., respectively [geometric mean ratio (95% CI) 0.71 (0.48, 1.05)].",A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28213957/),[ng] / [ml],743,77691,DB00559,Bosentan
,28213957,CmaxC,"The geometric mean (95% CI) for CmaxC was 743 ng ml-1 (573, 963) and 528 ng ml-1 (386, 722) for 2 mg kg-1 b.i.d. and t.i.d., respectively [geometric mean ratio (95% CI) 0.71 (0.48, 1.05)].",A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28213957/),[ng] / [ml],528,77692,DB00559,Bosentan
,28213957,tmax,"The median (range) for tmax was 3.0 h (0.0-7.5) and 3.0 h (1.0-8.0) for 2 mg kg-1 b.i.d. and t.i.d., respectively.",A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28213957/),h,3.0,77693,DB00559,Bosentan
,28213957,tmax,"The median (range) for tmax was 3.0 h (0.0-7.5) and 3.0 h (1.0-8.0) for 2 mg kg-1 b.i.d. and t.i.d., respectively.",A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28213957/),h,3.0,77694,DB00559,Bosentan
,15671601,cardiac index,"In 18 patients, mean pulmonary arterial pressure decreased from 52.4+/-13.8 to 46.8+/-13.8 mmHg (p=0.003) and cardiac index increased from 2.20+/-0.74 to 2.61 +/-0.72 L.min(-1).","Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671601/),[l] / [min],2.20,79018,DB00559,Bosentan
,15671601,cardiac index,"In 18 patients, mean pulmonary arterial pressure decreased from 52.4+/-13.8 to 46.8+/-13.8 mmHg (p=0.003) and cardiac index increased from 2.20+/-0.74 to 2.61 +/-0.72 L.min(-1).","Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671601/),[l] / [min],2.61,79019,DB00559,Bosentan
,15671601,dyspnea index,The dyspnea index (Borg scale) decreased from 3.2+/-2.4 to 2.2+/-1.7 (p=0.02).,"Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671601/),,3.2,79020,DB00559,Bosentan
,15671601,dyspnea index,The dyspnea index (Borg scale) decreased from 3.2+/-2.4 to 2.2+/-1.7 (p=0.02).,"Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671601/),,2.2,79021,DB00559,Bosentan
,27240565,flow rate,"Chromatographic separation was achieved on a Waters ACQUITY UPLC BEH C18 column (2.1 mm × 100 mm, 1.7 μm particle size, Waters Corp., Milford, MA, USA) and inline 0.2 μm stainless steel frit filter (Waters Corp.) with acetonitrile-0.1% formic acid as the mobile phase at a flow rate of 0.4 mL/min with gradient elution.","Simultaneous Determination of Bosentan, Glimepiride, HYBOS and M1 in Rat Plasma by UPLC-MS-MS and its Application to Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27240565/),[ml] / [min],0.4,87834,DB00559,Bosentan
,27240565,retention times,"The retention times were ∼3.29 min for BOS, 3.56 min for GLP, 1.42 min for HYBOS, 1.53 min for M1 and 3.22 min for IS.","Simultaneous Determination of Bosentan, Glimepiride, HYBOS and M1 in Rat Plasma by UPLC-MS-MS and its Application to Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27240565/),min,∼3.29,87835,DB00559,Bosentan
,27240565,retention times,"The retention times were ∼3.29 min for BOS, 3.56 min for GLP, 1.42 min for HYBOS, 1.53 min for M1 and 3.22 min for IS.","Simultaneous Determination of Bosentan, Glimepiride, HYBOS and M1 in Rat Plasma by UPLC-MS-MS and its Application to Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27240565/),min,3.56,87836,DB00559,Bosentan
,27240565,retention times,"The retention times were ∼3.29 min for BOS, 3.56 min for GLP, 1.42 min for HYBOS, 1.53 min for M1 and 3.22 min for IS.","Simultaneous Determination of Bosentan, Glimepiride, HYBOS and M1 in Rat Plasma by UPLC-MS-MS and its Application to Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27240565/),min,1.42,87837,DB00559,Bosentan
,27240565,retention times,"The retention times were ∼3.29 min for BOS, 3.56 min for GLP, 1.42 min for HYBOS, 1.53 min for M1 and 3.22 min for IS.","Simultaneous Determination of Bosentan, Glimepiride, HYBOS and M1 in Rat Plasma by UPLC-MS-MS and its Application to Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27240565/),min,1.53,87838,DB00559,Bosentan
,27240565,retention times,"The retention times were ∼3.29 min for BOS, 3.56 min for GLP, 1.42 min for HYBOS, 1.53 min for M1 and 3.22 min for IS.","Simultaneous Determination of Bosentan, Glimepiride, HYBOS and M1 in Rat Plasma by UPLC-MS-MS and its Application to Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27240565/),min,3.22,87839,DB00559,Bosentan
exceeded,27240565,recoveries,"The mean recoveries of BOS, GLP, HYBOS, M1 and ambrisentan from the plasma exceeded 90.4%.","Simultaneous Determination of Bosentan, Glimepiride, HYBOS and M1 in Rat Plasma by UPLC-MS-MS and its Application to Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27240565/),%,90.4,87840,DB00559,Bosentan
,24309556,flow rate,The four drugs were separated by high-performance liquid chromatography using a C18 column and an isocratic mobile phase running at a flow rate of 0.2mL/min for 5min.,"Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24309556/),[ml] / [min],0.2,88314,DB00559,Bosentan
,27162632,absorption rate constant,"Mean population estimates for riociguat absorption rate constant, clearance, and volume of distribution were 2.17/h, 1.81 L/h, and 32.3 L, respectively; for M1 they were 0.258/h, 3.16 L/h, and 124 L.",Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27162632/),1/[h],2.17,91089,DB00559,Bosentan
,27162632,clearance,"Mean population estimates for riociguat absorption rate constant, clearance, and volume of distribution were 2.17/h, 1.81 L/h, and 32.3 L, respectively; for M1 they were 0.258/h, 3.16 L/h, and 124 L.",Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27162632/),[l] / [h],1.81,91090,DB00559,Bosentan
,27162632,clearance,"Mean population estimates for riociguat absorption rate constant, clearance, and volume of distribution were 2.17/h, 1.81 L/h, and 32.3 L, respectively; for M1 they were 0.258/h, 3.16 L/h, and 124 L.",Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27162632/),[l] / [h],3.16,91091,DB00559,Bosentan
,27162632,volume of distribution,"Mean population estimates for riociguat absorption rate constant, clearance, and volume of distribution were 2.17/h, 1.81 L/h, and 32.3 L, respectively; for M1 they were 0.258/h, 3.16 L/h, and 124 L.",Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27162632/),l,32.3,91092,DB00559,Bosentan
,27162632,volume of distribution,"Mean population estimates for riociguat absorption rate constant, clearance, and volume of distribution were 2.17/h, 1.81 L/h, and 32.3 L, respectively; for M1 they were 0.258/h, 3.16 L/h, and 124 L.",Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27162632/),l,124,91093,DB00559,Bosentan
,22511577,peak plasma concentration,"Pharmacokinetics were evaluated in sixteen children treated with ambrisentan from 2.5 mg to 10.0 mg; the mean peak plasma concentration was 738 ± 452 ng/ml, mean time to peak plasma concentration was 3.2 ± 2.1 hours, and mean area under the curve plasma concentration was 6657 ± 4246 ng·hour/ml.","Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511577/),[ng] / [ml],738,93523,DB00559,Bosentan
,22511577,time to peak plasma concentration,"Pharmacokinetics were evaluated in sixteen children treated with ambrisentan from 2.5 mg to 10.0 mg; the mean peak plasma concentration was 738 ± 452 ng/ml, mean time to peak plasma concentration was 3.2 ± 2.1 hours, and mean area under the curve plasma concentration was 6657 ± 4246 ng·hour/ml.","Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511577/),h,3.2,93524,DB00559,Bosentan
,22511577,area under the curve plasma concentration,"Pharmacokinetics were evaluated in sixteen children treated with ambrisentan from 2.5 mg to 10.0 mg; the mean peak plasma concentration was 738 ± 452 ng/ml, mean time to peak plasma concentration was 3.2 ± 2.1 hours, and mean area under the curve plasma concentration was 6657 ± 4246 ng·hour/ml.","Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511577/),[h·ng] / [ml],6657,93525,DB00559,Bosentan
,25581063,apparent clearance (CL/F),"The population mean estimates of apparent clearance (CL/F) and volume (V/F) were 10.8 l h(-1) (95% CI 9.2, 12.4 l h(-1) ) and 267 l (95% CI 208, 326 l), respectively.","Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25581063/),[l] / [h],10.8,100930,DB00559,Bosentan
,25581063,volume (V/F),"The population mean estimates of apparent clearance (CL/F) and volume (V/F) were 10.8 l h(-1) (95% CI 9.2, 12.4 l h(-1) ) and 267 l (95% CI 208, 326 l), respectively.","Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25581063/),l,267,100931,DB00559,Bosentan
,19639656,constant infusion rate (I),"Bosentan was administered intravenously at a constant infusion rate (I) of 24, 40 or 60 microg/min/kg.",Mechanisms responsible for the altered pharmacokinetics of bosentan: analysis utilizing rats with bile duct ligation-induced liver dysfunction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19639656/),[μg] / [kg·min],24,108764,DB00559,Bosentan
,19639656,constant infusion rate (I),"Bosentan was administered intravenously at a constant infusion rate (I) of 24, 40 or 60 microg/min/kg.",Mechanisms responsible for the altered pharmacokinetics of bosentan: analysis utilizing rats with bile duct ligation-induced liver dysfunction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19639656/),[μg] / [kg·min],40,108765,DB00559,Bosentan
,19639656,constant infusion rate (I),"Bosentan was administered intravenously at a constant infusion rate (I) of 24, 40 or 60 microg/min/kg.",Mechanisms responsible for the altered pharmacokinetics of bosentan: analysis utilizing rats with bile duct ligation-induced liver dysfunction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19639656/),[μg] / [kg·min],60,108766,DB00559,Bosentan
,19639656,CL,"The CL values in normal rats were 30.5 and 19.3 ml/min/kg at infusion rates of 24 and 60 microg/min/kg, respectively, suggesting non-linear pharmacokinetics of bosentan.",Mechanisms responsible for the altered pharmacokinetics of bosentan: analysis utilizing rats with bile duct ligation-induced liver dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19639656/),[ml] / [kg·min],30.5,108767,DB00559,Bosentan
,19639656,CL,"The CL values in normal rats were 30.5 and 19.3 ml/min/kg at infusion rates of 24 and 60 microg/min/kg, respectively, suggesting non-linear pharmacokinetics of bosentan.",Mechanisms responsible for the altered pharmacokinetics of bosentan: analysis utilizing rats with bile duct ligation-induced liver dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19639656/),[ml] / [kg·min],19.3,108768,DB00559,Bosentan
,19639656,CL,"The BBC in BDL rats was much higher than that in normal rats, and the CL values in BDL rats were 3.80 and 3.08 ml/min/kg at infusion rates of 24 and 60 microg/min/kg, respectively.",Mechanisms responsible for the altered pharmacokinetics of bosentan: analysis utilizing rats with bile duct ligation-induced liver dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19639656/),[ml] / [kg·min],3.80,108769,DB00559,Bosentan
,19639656,CL,"The BBC in BDL rats was much higher than that in normal rats, and the CL values in BDL rats were 3.80 and 3.08 ml/min/kg at infusion rates of 24 and 60 microg/min/kg, respectively.",Mechanisms responsible for the altered pharmacokinetics of bosentan: analysis utilizing rats with bile duct ligation-induced liver dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19639656/),[ml] / [kg·min],3.08,108770,DB00559,Bosentan
,32539916,total run time,The total run time for a single injection was within 10 min.,"Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32539916/),min,10,123308,DB00559,Bosentan
,29019117,"unbound partitioning (Kpu,u)","In vivo unbound partitioning (Kpu,u) for rosuvastatin, bosentan, and metformin, calculated from total concentrations in the liver and plasma, were 243, 553, and 15, respectively.",Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29019117/),,243,129954,DB00559,Bosentan
,29019117,"unbound partitioning (Kpu,u)","In vivo unbound partitioning (Kpu,u) for rosuvastatin, bosentan, and metformin, calculated from total concentrations in the liver and plasma, were 243, 553, and 15, respectively.",Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29019117/),,553,129955,DB00559,Bosentan
,29019117,"unbound partitioning (Kpu,u)","In vivo unbound partitioning (Kpu,u) for rosuvastatin, bosentan, and metformin, calculated from total concentrations in the liver and plasma, were 243, 553, and 15, respectively.",Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29019117/),,15,129956,DB00559,Bosentan
,12603176,areas under the plasma concentration-time curve over one administration interval of 12 hours (AUC(tau)),The pharmacokinetic parameters of bosentan and its metabolites were not influenced by concomitant treatment with simvastatin: areas under the plasma concentration-time curve over one administration interval of 12 hours (AUC(tau)) [geometric mean and 95% CI] were 4586 (3719-5656) and 4928 (3945-6156) micro g * h/L.,"Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603176/),[h·μg] / [l],4586,148575,DB00559,Bosentan
,12603176,areas under the plasma concentration-time curve over one administration interval of 12 hours (AUC(tau)),The pharmacokinetic parameters of bosentan and its metabolites were not influenced by concomitant treatment with simvastatin: areas under the plasma concentration-time curve over one administration interval of 12 hours (AUC(tau)) [geometric mean and 95% CI] were 4586 (3719-5656) and 4928 (3945-6156) micro g * h/L.,"Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603176/),[h·μg] / [l],4928,148576,DB00559,Bosentan
,12603176,AUC(tau),"AUC(tau) values for simvastatin were 30.5 (23.1-40.2) and 20.0 (15.9-25.1) micro g * h/L and for beta-hydroxyacid simvastatin 43.0 (32.1-57.8) and 23.4 (16.7-32.6) micro g * h/L in treatments B and C, respectively.","Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603176/),[h·μg] / [l],30.5,148577,DB00559,Bosentan
,12603176,AUC(tau),"AUC(tau) values for simvastatin were 30.5 (23.1-40.2) and 20.0 (15.9-25.1) micro g * h/L and for beta-hydroxyacid simvastatin 43.0 (32.1-57.8) and 23.4 (16.7-32.6) micro g * h/L in treatments B and C, respectively.","Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603176/),[h·μg] / [l],20.0,148578,DB00559,Bosentan
,12603176,AUC(tau),"AUC(tau) values for simvastatin were 30.5 (23.1-40.2) and 20.0 (15.9-25.1) micro g * h/L and for beta-hydroxyacid simvastatin 43.0 (32.1-57.8) and 23.4 (16.7-32.6) micro g * h/L in treatments B and C, respectively.","Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603176/),[h·μg] / [l],43.0,148579,DB00559,Bosentan
,12603176,AUC(tau),"AUC(tau) values for simvastatin were 30.5 (23.1-40.2) and 20.0 (15.9-25.1) micro g * h/L and for beta-hydroxyacid simvastatin 43.0 (32.1-57.8) and 23.4 (16.7-32.6) micro g * h/L in treatments B and C, respectively.","Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603176/),[h·μg] / [l],23.4,148580,DB00559,Bosentan
,11865964,Cmax,"The pharmacokinetic parameters of bosentan (and also three of its metabolites) were very similar after the four treatments: geometric means for Cmax and AUC0-infinity, ranged from 1.3 to 1.6 microg/ml and from 7.8 to 8.9 microg x h/ml, respectively, and median t(max) from 3.0 to 4.0 hours.","Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865964/),[μg] / [ml],1.3 to 1.6,149005,DB00559,Bosentan
,11865964,AUC0-infinity,"The pharmacokinetic parameters of bosentan (and also three of its metabolites) were very similar after the four treatments: geometric means for Cmax and AUC0-infinity, ranged from 1.3 to 1.6 microg/ml and from 7.8 to 8.9 microg x h/ml, respectively, and median t(max) from 3.0 to 4.0 hours.","Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865964/),[h·μg] / [ml],7.8 to 8.9,149006,DB00559,Bosentan
,11865964,t(max),"The pharmacokinetic parameters of bosentan (and also three of its metabolites) were very similar after the four treatments: geometric means for Cmax and AUC0-infinity, ranged from 1.3 to 1.6 microg/ml and from 7.8 to 8.9 microg x h/ml, respectively, and median t(max) from 3.0 to 4.0 hours.","Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865964/),h,3.0 to 4.0,149007,DB00559,Bosentan
,11865964,bioavailability,"The bioavailability of the 125 mg tablet relative to that of the suspension, both given fasted, was 102%.","Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865964/),%,102,149008,DB00559,Bosentan
,27478783,PDI,"Particle size, PDI and yield of the optimal nanosuspension formulation were 200.9 nm, 0.24 and 99.6%, respectively.",D-optimal Design for Preparation and Optimization of Fast Dissolving Bosentan Nanosuspension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27478783/),,0,154449,DB00559,Bosentan
,33558262,maximum target occupancies,"By analyzing blood PK profiles alone, the PBPK model with target binding yielded practically identifiable target binding parameters and predicted the maximum target occupancies of 0.6-0.8 at clinical bosentan doses.","Revisiting Nonlinear Bosentan Pharmacokinetics by Physiologically Based Pharmacokinetic Modeling: Target Binding, Albeit Not a Major Contributor to Nonlinearity, Can Offer Prediction of Target Occupancy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33558262/),,0.6-0.8,159500,DB00559,Bosentan
,10383550,steady-state Cmax,"Average steady-state Cmax and Ctr were 2-2.1 microg l-1 and 0.65-0.69 microg l-1, respectively, when given alone.",The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383550/),[μg] / [l],2-2.1,169616,DB00559,Bosentan
,10383550,Ctr,"Average steady-state Cmax and Ctr were 2-2.1 microg l-1 and 0.65-0.69 microg l-1, respectively, when given alone.",The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383550/),[μg] / [l],0.65-0.69,169617,DB00559,Bosentan
,10383550,Cmax,"Bosentan pharmacokinetic parameters after 1 week of treatment were as expected with a mean Cmax of 3260 microg l-1 and a mean AUC (0, 12h) of 12 600 microg l-1 h.",The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383550/),[μg] / [l],3260,169618,DB00559,Bosentan
,10383550,"AUC (0, 12h)","Bosentan pharmacokinetic parameters after 1 week of treatment were as expected with a mean Cmax of 3260 microg l-1 and a mean AUC (0, 12h) of 12 600 microg l-1 h.",The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383550/),[h·μg] / [l],12 600,169619,DB00559,Bosentan
,12631050,CBF,"In group 1, baseline CBF was 55 +/- 7 ml/100 cm3/min.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],55,176357,DB00559,Bosentan
,12631050,CBF,Indomethacin decreased CBF to 41 +/- 5 ml/100 cm3/min (P < 0.002).,No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],41,176358,DB00559,Bosentan
,12631050,CBF,"In group 2, baseline CBF was 54 +/- 10 ml/100 cm3/min.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],54,176359,DB00559,Bosentan
,12631050,CBF,Placebo did not change CBF while indomethacin decreased CBF significantly to 41 +/- 5 ml/100 cm3/min (P < 0.002).,No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],41,176360,DB00559,Bosentan
,12631050,Total plasma concentrations,"Total plasma concentrations of bosentan at the time of the first and the second PET measurement were 3.9 and 1.4 microg/ml, respectively.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[μg] / [ml],3.9,176361,DB00559,Bosentan
,12631050,Total plasma concentrations,"Total plasma concentrations of bosentan at the time of the first and the second PET measurement were 3.9 and 1.4 microg/ml, respectively.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[μg] / [ml],1.4,176362,DB00559,Bosentan
,12520623,Cmax,"The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng.h/ml after single doses and were 1831 and 1715 ng/ml and 7216 and 7838 ng.h/ml after multiple doses, respectively, in healthy subjects and patients.","Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520623/),[ng] / [ml],2534,188953,DB00559,Bosentan
,12520623,Cmax,"The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng.h/ml after single doses and were 1831 and 1715 ng/ml and 7216 and 7838 ng.h/ml after multiple doses, respectively, in healthy subjects and patients.","Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520623/),[ng] / [ml],1980,188954,DB00559,Bosentan
,12520623,Cmax,"The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng.h/ml after single doses and were 1831 and 1715 ng/ml and 7216 and 7838 ng.h/ml after multiple doses, respectively, in healthy subjects and patients.","Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520623/),[ng] / [ml],1831,188955,DB00559,Bosentan
,12520623,Cmax,"The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng.h/ml after single doses and were 1831 and 1715 ng/ml and 7216 and 7838 ng.h/ml after multiple doses, respectively, in healthy subjects and patients.","Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520623/),[ng] / [ml],1715,188956,DB00559,Bosentan
,12520623,Cmax,"The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng.h/ml after single doses and were 1831 and 1715 ng/ml and 7216 and 7838 ng.h/ml after multiple doses, respectively, in healthy subjects and patients.","Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520623/),[h·ng] / [ml],7216,188957,DB00559,Bosentan
,12520623,AUC,"The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng.h/ml after single doses and were 1831 and 1715 ng/ml and 7216 and 7838 ng.h/ml after multiple doses, respectively, in healthy subjects and patients.","Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520623/),[ng] / [ml],1980,188958,DB00559,Bosentan
,12520623,AUC,"The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng.h/ml after single doses and were 1831 and 1715 ng/ml and 7216 and 7838 ng.h/ml after multiple doses, respectively, in healthy subjects and patients.","Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520623/),[h·ng] / [ml],"11,957",188959,DB00559,Bosentan
,12520623,AUC,"The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng.h/ml after single doses and were 1831 and 1715 ng/ml and 7216 and 7838 ng.h/ml after multiple doses, respectively, in healthy subjects and patients.","Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520623/),[h·ng] / [ml],"10,781",188960,DB00559,Bosentan
,12520623,AUC,"The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng.h/ml after single doses and were 1831 and 1715 ng/ml and 7216 and 7838 ng.h/ml after multiple doses, respectively, in healthy subjects and patients.","Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520623/),[h·ng] / [ml],7216,188961,DB00559,Bosentan
,12520623,AUC,"The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng.h/ml after single doses and were 1831 and 1715 ng/ml and 7216 and 7838 ng.h/ml after multiple doses, respectively, in healthy subjects and patients.","Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520623/),[h·ng] / [ml],7838,188962,DB00559,Bosentan
,21383523,CL/F,"The final population mean values of CL/F and k were estimated to be 0.409 · (1 - 0.0377 · (AGE - 3.81)) · WT L/h and 0.175 h(-1), respectively.",Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21383523/),,0.409,197956,DB00559,Bosentan
,21383523,k,"The final population mean values of CL/F and k were estimated to be 0.409 · (1 - 0.0377 · (AGE - 3.81)) · WT L/h and 0.175 h(-1), respectively.",Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21383523/),1/[h],0.175,197957,DB00559,Bosentan
,10392325,oral bioavailability,"The oral bioavailability of bosentan was 43% to 48%, with a small interindividual variability of 20%.","Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392325/),%,43,199485,DB00559,Bosentan
,10392325,oral bioavailability,"The oral bioavailability of bosentan was 43% to 48%, with a small interindividual variability of 20%.","Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392325/),%,48,199486,DB00559,Bosentan
,31222765,steady-state AUCτ,Tadalafil's median (range) steady-state AUCτ at the high dose was 7243 (3131-13 088) ng•h/mL across all patients.,Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension: A multiple ascending-dose study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31222765/),[h·ng] / [ml],7243,203452,DB00559,Bosentan
,25874072,Cthrough,"The patient had a sildenafil Cthrough and Cmax of 276.94 ng/mL and 1733.19 ng/mL, respectively.",Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus- infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25874072/),[ng] / [ml],276.94,209788,DB00559,Bosentan
,25874072,Cmax,"The patient had a sildenafil Cthrough and Cmax of 276.94 ng/mL and 1733.19 ng/mL, respectively.",Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus- infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25874072/),[ng] / [ml],1733.19,209789,DB00559,Bosentan
,25874072,Cthrough,"The Cthrough and the Cmax of bosentan were 1546.53 ng/mL and 3365.99 ng/mL, respectively.",Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus- infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25874072/),[ng] / [ml],1546.53,209790,DB00559,Bosentan
,25874072,Cmax,"The Cthrough and the Cmax of bosentan were 1546.53 ng/mL and 3365.99 ng/mL, respectively.",Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus- infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25874072/),[ng] / [ml],3365.99,209791,DB00559,Bosentan
,12139208,Cmax,"The pharmacokinetic parameters of bosentan did not differ significantly between the study groups: geometric means (95% confidence interval) for Cmax were 1.8 (1.2 - 2.8) and 1.1 microg/ml (0.74 - 1.7), and for AUC0-infinity 7.2 (5.1 - 10.4) and 6.4 (3.4 - 11.2) microg x h/ml in healthy subjects and renal patients, respectively.","Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139208/),[μg] / [ml],1.8,215053,DB00559,Bosentan
,12139208,Cmax,"The pharmacokinetic parameters of bosentan did not differ significantly between the study groups: geometric means (95% confidence interval) for Cmax were 1.8 (1.2 - 2.8) and 1.1 microg/ml (0.74 - 1.7), and for AUC0-infinity 7.2 (5.1 - 10.4) and 6.4 (3.4 - 11.2) microg x h/ml in healthy subjects and renal patients, respectively.","Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139208/),[μg] / [ml],1.1,215054,DB00559,Bosentan
,12139208,AUC0-infinity,"The pharmacokinetic parameters of bosentan did not differ significantly between the study groups: geometric means (95% confidence interval) for Cmax were 1.8 (1.2 - 2.8) and 1.1 microg/ml (0.74 - 1.7), and for AUC0-infinity 7.2 (5.1 - 10.4) and 6.4 (3.4 - 11.2) microg x h/ml in healthy subjects and renal patients, respectively.","Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139208/),[h·μg] / [ml],7.2,215055,DB00559,Bosentan
,12139208,AUC0-infinity,"The pharmacokinetic parameters of bosentan did not differ significantly between the study groups: geometric means (95% confidence interval) for Cmax were 1.8 (1.2 - 2.8) and 1.1 microg/ml (0.74 - 1.7), and for AUC0-infinity 7.2 (5.1 - 10.4) and 6.4 (3.4 - 11.2) microg x h/ml in healthy subjects and renal patients, respectively.","Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139208/),[h·μg] / [ml],6.4,215056,DB00559,Bosentan
,24745065,terminal half-life,The mean terminal half-life of bosentan was 20.4 ± 17.2 h.,"Pharmacokinetics and preliminary safety data of a single oral dose of bosentan, a dual endothelin receptor antagonist, in cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24745065/),h,20.4,220564,DB00559,Bosentan
,24745065,peak plasma concentration,"The mean peak plasma concentration was 0.49 ± 0.24 g/mL, and the mean time to maximum plasma concentration was 6.8 ± 8.6 h.","Pharmacokinetics and preliminary safety data of a single oral dose of bosentan, a dual endothelin receptor antagonist, in cats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24745065/),[g] / [ml],0.49,220565,DB00559,Bosentan
,24745065,time to maximum plasma concentration,"The mean peak plasma concentration was 0.49 ± 0.24 g/mL, and the mean time to maximum plasma concentration was 6.8 ± 8.6 h.","Pharmacokinetics and preliminary safety data of a single oral dose of bosentan, a dual endothelin receptor antagonist, in cats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24745065/),h,6.8,220566,DB00559,Bosentan
,24745065,area under the curve,The area under the curve was 5.14 ± 3.81 h·μg/mL.,"Pharmacokinetics and preliminary safety data of a single oral dose of bosentan, a dual endothelin receptor antagonist, in cats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24745065/),[h·μg] / [ml],5.14,220567,DB00559,Bosentan
,16550733,Cmax,"In the absence of bosentan, the pharmacokinetics of norethisterone and ethinyl estradiol were characterized by Cmax and AUC0-infinity values (95% CI) of 9.8 (8.1, 11.9) ng/ml and 72.9 (57.0, 93.1) ng x h/ml, and 53.0 (47.0, 59.9) pg/ml and 758 (655, 878) pg x h/ml, respectively.",Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16550733/),[ng] / [ml],9.8,229682,DB00559,Bosentan
,16550733,AUC0-infinity,"In the absence of bosentan, the pharmacokinetics of norethisterone and ethinyl estradiol were characterized by Cmax and AUC0-infinity values (95% CI) of 9.8 (8.1, 11.9) ng/ml and 72.9 (57.0, 93.1) ng x h/ml, and 53.0 (47.0, 59.9) pg/ml and 758 (655, 878) pg x h/ml, respectively.",Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16550733/),[h·ng] / [ml],72.9,229683,DB00559,Bosentan
,16550733,AUC0-infinity,"In the absence of bosentan, the pharmacokinetics of norethisterone and ethinyl estradiol were characterized by Cmax and AUC0-infinity values (95% CI) of 9.8 (8.1, 11.9) ng/ml and 72.9 (57.0, 93.1) ng x h/ml, and 53.0 (47.0, 59.9) pg/ml and 758 (655, 878) pg x h/ml, respectively.",Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16550733/),[h·pg] / [ml],758,229684,DB00559,Bosentan
,15112184,clearance,"On the basis of analyzing samples from Genius-hemodialysis by a liquid chromatography assay with tandem mass spectrometry detection, the authors determined the bosentan dialysis clearance to be as low as 3.5 mL/min.",Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15112184/),[ml] / [min],3.5,233983,DB00559,Bosentan
,30725476,flow rate,"Chromatographic separation was performed on a reverse-phase C18 column (5 μm, 4.6 × 150 mm) with an isocratic mobile phase, which consisted of water containing 0.2% acetic acid-acetonitrile (90:10, v/v) at a flow rate of 1 mL/min.","A novel, rapid and sensitive UPLC-MS/MS method for the determination of macitentan in patients with pulmonary arterial hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30725476/),[ml] / [min],1,251346,DB00559,Bosentan
,30725476,Retention times,"Retention times were 1.97 and 1.72 min for macitentan and IS, respectively.","A novel, rapid and sensitive UPLC-MS/MS method for the determination of macitentan in patients with pulmonary arterial hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30725476/),min,1.97,251347,DB00559,Bosentan
,30725476,Retention times,"Retention times were 1.97 and 1.72 min for macitentan and IS, respectively.","A novel, rapid and sensitive UPLC-MS/MS method for the determination of macitentan in patients with pulmonary arterial hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30725476/),min,1.72,251348,DB00559,Bosentan
,30725476,recovery,"The lower limit of quantitation and average recovery values were determined as 1 ng/mL and 89.8%, respectively.","A novel, rapid and sensitive UPLC-MS/MS method for the determination of macitentan in patients with pulmonary arterial hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30725476/),%,89.8,251349,DB00559,Bosentan
,24872209,CL/F,"The mean CL/F and V/F values of tadalafil were 0.149 L·h-1·kg-1 and 1.87 L/kg, respectively, which were higher than those reported in adults.",Plasma concentrations of tadalafil in children with pulmonary arterial hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24872209/),[l] / [h·kg],0.149,251414,DB00559,Bosentan
,24872209,V/F,"The mean CL/F and V/F values of tadalafil were 0.149 L·h-1·kg-1 and 1.87 L/kg, respectively, which were higher than those reported in adults.",Plasma concentrations of tadalafil in children with pulmonary arterial hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24872209/),[l] / [kg],1.87,251415,DB00559,Bosentan
,24872209,unbound tadalafil,"The unbound tadalafil concentrations of the postdose samples ranged from 5.9 to 146 (46.9 ± 37.1) nmol/L, higher than the reported IC50 value of this phosphodiesterase-5 drug for humans (2-4 nmol/L, corresponding to 0.8-1.6 ng/mL).",Plasma concentrations of tadalafil in children with pulmonary arterial hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24872209/),[nM] / [l],5.9 to 146,251416,DB00559,Bosentan
,24872209,unbound tadalafil,"The unbound tadalafil concentrations of the postdose samples ranged from 5.9 to 146 (46.9 ± 37.1) nmol/L, higher than the reported IC50 value of this phosphodiesterase-5 drug for humans (2-4 nmol/L, corresponding to 0.8-1.6 ng/mL).",Plasma concentrations of tadalafil in children with pulmonary arterial hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24872209/),[nM] / [l],46.9,251417,DB00559,Bosentan
,24872209,concentrations,"The unbound tadalafil concentrations of the postdose samples ranged from 5.9 to 146 (46.9 ± 37.1) nmol/L, higher than the reported IC50 value of this phosphodiesterase-5 drug for humans (2-4 nmol/L, corresponding to 0.8-1.6 ng/mL).",Plasma concentrations of tadalafil in children with pulmonary arterial hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24872209/),[nM] / [l],5.9 to 146,251418,DB00559,Bosentan
,24872209,concentrations,"The unbound tadalafil concentrations of the postdose samples ranged from 5.9 to 146 (46.9 ± 37.1) nmol/L, higher than the reported IC50 value of this phosphodiesterase-5 drug for humans (2-4 nmol/L, corresponding to 0.8-1.6 ng/mL).",Plasma concentrations of tadalafil in children with pulmonary arterial hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24872209/),[nM] / [l],46.9,251419,DB00559,Bosentan
,24872209,IC50,"The unbound tadalafil concentrations of the postdose samples ranged from 5.9 to 146 (46.9 ± 37.1) nmol/L, higher than the reported IC50 value of this phosphodiesterase-5 drug for humans (2-4 nmol/L, corresponding to 0.8-1.6 ng/mL).",Plasma concentrations of tadalafil in children with pulmonary arterial hypertension. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24872209/),[nM] / [l],2-4,251420,DB00559,Bosentan
,24872209,IC50,"The unbound tadalafil concentrations of the postdose samples ranged from 5.9 to 146 (46.9 ± 37.1) nmol/L, higher than the reported IC50 value of this phosphodiesterase-5 drug for humans (2-4 nmol/L, corresponding to 0.8-1.6 ng/mL).",Plasma concentrations of tadalafil in children with pulmonary arterial hypertension. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24872209/),[ng] / [ml],0.8-1.6,251421,DB00559,Bosentan
,28156176,bioavailability,"The oral delivery of bosentan possesses several drawbacks such as low bioavailability (about 50%), short duration of action, frequent administration, hepatotoxicity and systemic hypotension.","Respirable controlled release polymeric colloid (RCRPC) of bosentan for the management of pulmonary hypertension: in vitro aerosolization, histological examination and in vivo pulmonary absorption. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28156176/),%,50,256087,DB00559,Bosentan
,15963102,C(max),Sildenafil C(max) fell from 759 ng ml(-1) on visit 1 to 333 ng ml(-1) on visit 3 (P < 0.01) and there was a significant decrease in the plasma half-life of sildenafil on the higher bosentan dose (P < 0.05).,Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15963102/),[ng] / [ml],759,269282,DB00559,Bosentan
,15963102,C(max),Sildenafil C(max) fell from 759 ng ml(-1) on visit 1 to 333 ng ml(-1) on visit 3 (P < 0.01) and there was a significant decrease in the plasma half-life of sildenafil on the higher bosentan dose (P < 0.05).,Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15963102/),[ng] / [ml],333,269283,DB00559,Bosentan
